Biliary Stent Insertion Research Articles

Technical refinements to reduce the early biliary complication in living donor liver transplantation

BackgroundBiliary reconstruction is a key factor that affects biliary complication rates. Surgical experience plays a pivotal role, but continuous technical refinement is essential for enhancing biliary outcomes. This study aimed to evaluate the biliary outcomes of LDLTs in patients undergoing microsurgical biliary reconstruction with continual technical refinements. Materials and MethodsThis observational cohort study analyzed data was conducted from 2006 to 2022. Microsurgical biliary reconstruction was performed using various refinements, including selective biliary stent insertion, ipsilateral (anatomical) bile duct anastomosis, use of a figure-of-8 suture over the junction of the graft and recipient bile ducts, and centralization techniques for size discrepancies greater than 2 to 1. Comparison and evaluation of early BC within one year post transplant was performed. Results1780 patients (including 1563 adults and 217 paediatric patients) underwent microsurgical biliary reconstruction in LDLTs at KCGMH between 2006 and 2022. The donor grafts comprised 1109 right liver grafts and 671 left liver grafts. Of the grafts, 23.1 % had multiple bile ducts and 16.1 % had bile duct sizes <3 mm. Duct-to-duct anastomosis was performed in most cases 1417 (79.6 %), while 363 (20.4 %) Roux-en-Y hepaticojejunostomies (RY HJ) was performed. The overall early BCs rate was 10 % and notable improvements were observed, decreasing from 10.35 % between 2006 and 2021 to 6.5 % by 2022. Early BS comprised the most part of 6.1 % as compared to 2.7 % one year after transplantation. Stent insertion in selected cases, ipsilateral anastomosis, and the figure-of-8 suture technique significantly reduced early BCs. Although centralization technique showed promising results, its effect was not statistically significant. ConclusionsContinual technical refinements in MBR can contribute to a substantial reduction in early BCs following LDLT, ultimately leading to improved patient outcomes.

Optimising the indications for biliary stent placement during endoscopic retrograde cholangiopancreatography: a quality improvement initiative to enhance patient care and reduce healthcare resource utilisation

BackgroundA retrospective chart audit was performed to review biliary stent utilisation from January 2020 to January 2021. Non-guideline-based stent insertion was identified in 16% of patients with common bile duct...

Placing Plastic Stent via Percutaneous Transhepatic Biliary Drainage following Failure of Endoscopic Retrograde Cholangiopancreatography: Review of Case Series

AbstractThe aim of this study is to describe the technical procedure, patency, and complications of percutaneous biliary plastic stent insertion following failure of the endoscopic approach. The data from 11 patients who underwent percutaneous plastic biliary stent placement following endoscopic approach failure between March 2022 and December 2023 were retrospectively evaluated. Stent placement was successful in all patients. Reduction of the total serum bilirubin level was achieved in all patients. No major complications occurred in all patients. A plastic stent provided enough drainage for patients with patency in our studies for up to 5 months.

Anti-fibrotic and anti-stricture effects of biodegradable biliary stents braided with dexamethasone-impregnated sheath/core structured monofilaments

Endoscopic biliary stent insertion has been widely used for the treatment of benign biliary stricture (BBS). Thus, the development of stent materials in the perspectives of structure, mechanical properties, and biocompatibility has been also studied. However, conventional metal and plastic stents have several disadvantages, such as repeated procedures to remove or exchange them, dislodgment, restenosis, biocompatibility, and poor mechanical properties. Sustainable effectiveness, attenuation and prevention of fibrosis, and biocompatibility are key factors for the clinical application of stents to BBS treatment. In addition, loading drugs could show synergistic effects with stents’ own performance. We developed a dexamethasone-eluting biodegradable stent (DBS) consisting of a sheath/core structure with outstanding mechanical properties and sustained release of dexamethasone, which maintained its functions in a BBS duct over 12 weeks in a swine model. The insertion of our DBS not only expanded BBS areas but also healed secondary ulcers as a result of the attenuation of fibrosis. After 16 weeks from the insertion, BBS areas were totally improved, and the DBS was degraded and thoroughly disappeared without re-intervention for stent removal. Our DBS would be an effective clinical tool for non-vascular diseases. Statement of significanceThis study describes the insertion of a drug-eluting biodegradable stent (DBS) into the bile duct. The sheath/core structure of DBS confers substantial durability and a sustained drug release profile. Drug released from the DBS exhibited anti-fibrotic effects without inflammatory responses in both in vitro and in vivo experiments. The DBS maintained its function over 12 weeks after insertion into the common bile duct, expanding benign biliary stricture (BBS) and reducing inflammation to heal secondary ulcers in a swine BBS model. After 16 weeks from the DBS insertion, the DBS thoroughly disappeared without re-intervention for stent removal, resulting in totally improved BBS areas. Our findings not only spotlight the understanding of the sheath/core structure of the biodegradable stent, but also pave the way for the further application for non-vascular diseases.

HPB O03 ERCPs and Biliary Stenting for Ductal Stone Disease: A Call for a National Database

Abstract Background According to the European Society of Gastrointestinal Endoscopy, in the context of complicated biliary stone disease, plastic stenting of the biliary tree via endoscopic retrograde cholangiopancreatography (ERCP) temporarily provides drainage of a blocked or infected biliary system. However, there is high mortality and morbidity associated with long-term endoprostheses; cholangitis as one of the main complications. Therefore, plastic stenting should only be used for a period of up to 6 months, according to latest guidelines. Our aim was to compare Trust practice with international recommendations, identifying potential causes for prolonged stent placement in patients with choledocholithiasis, and to discuss possible solutions. Methods Patients who underwent an ERCP across a 3-year period from NHS secure server records were identified, with further analysis of patients undergoing plastic biliary stent insertion. Results Of the 1118 ERCPs performed, 281 underwent plastic stenting for choledocholithiasis. Some patients were not suitable for cholecystectomy, so stents were accepted as the ceiling of care. 29 had stents in situ for over 6 months, while waiting for surgery. Of the 75 who had proceeded to cholecystectomy, 57 subsequently had stents removed in the trust. 18 still had plastic stents in situ. 5 had stents removed elsewhere, one of whom developed cholangitis and sepsis, requiring removal of the infected stent at a tertiary centre. Two patients were no longer fit for removal, and two had spontaneously passed their stents. Conclusions Retained biliary stents is not a rarity. There are many factors leading to delays, including long waiting lists for surgery, lack of requests to the endoscopy department and patient choice. Extrapolation of this single-trust audit would suggest that many sites are not meeting international guidelines for the duration of indwelling plastic stents. We suggest the implementation of a national database to monitor all patients with biliary endoprostheses to reduce morbidity associated with retained stents. We also recommend that incidents where harm is caused by plastic stents remaining in situ for greater than six months be treated as a Never Event.

Current Therapeutics in Primary Sclerosing Cholangitis.

Primary sclerosing cholangitis (PSC) is an orphan, cholestatic liver disease that is characterized by inflammatory biliary strictures with variable progression to end-stage liver disease. Its pathophysiology is poorly understood. Chronic biliary inflammation is likely driven by immune dysregulation, gut dysbiosis, and environmental exposures resulting in gut-liver crosstalk and bile acid metabolism disturbances. There is no proven medical therapy that alters disease progression in PSC, with the commonly prescribed ursodeoxycholic acid being shown to improve liver biochemistry at low-moderate doses (15-23 mg/kg/day) but not alter transplant-free survival or liver-related outcomes. Liver transplantation is the only option for patients who develop end-stage liver disease or refractory complications of PSC. Immunosuppressive and antifibrotic agents have not proven to be effective, but there is promise for manipulation of the gut microbiome with fecal microbiota transplantation and antibiotics. Bile acid manipulation via alternate synthetic bile acids such as norursodeoxycholic acid, or interaction at a transcriptional level via nuclear receptor agonists and fibrates have shown potential in phase II trials in PSC with several leading to larger phase III trials. In view of the enhanced malignancy risk, statins, and aspirin show potential for reducing the risk of colorectal cancer and cholangiocarcinoma in PSC patients. For patients who develop clinically relevant strictures with cholestatic symptoms and worsening liver function, balloon dilatation is safer compared with biliary stent insertion with equivalent clinical efficacy.

Percutaneous insertion of long-covered biliary stents in patients with malignant duodenobiliary stricture.

To investigate the technical feasibility, safety, and efficacy of a long-covered biliary stent in patients with malignant duodenobiliary stricture. This retrospective study enrolled 57 consecutive patients (34 men, 23 women; mean age, 64years; range, 32-85years) who presented with malignant duodenobiliary stricture between February 2019 and November 2020. All patients were treated with a long (18 or 23cm)-covered biliary stent. The biliary stent deployment was technically successful in all 57 patients. The overall adverse event rate was 17.5% (10 of 57 patients). Successful internal drainage was achieved in 55 (96.5%) of 57 patients. The median patient survival and stent patency times were 99days (95% confidence interval [CI], 58-140days) and 73days (95% CI, 60-86days), respectively. Fourteen (25.5%) of the fifty-five patients presented with biliary stent dysfunction due to sludge (n = 11), tumor overgrowth (n = 1), collapse of the long biliary stent by a subsequently inserted additional duodenal stent (n = 1), or rapidly progressed duodenal cancer (n = 1). A univariate Cox proportional hazards model did not reveal any independent predictor of biliary stent patency. Percutaneous insertion of a subsequent biliary stent was technically feasible after duodenal stent insertion. Percutaneous insertion of a long-covered biliary stent was safe and effective in patients with malignant duodenobiliary stricture. In patients with malignant duodenobiliary stricture, percutaneous insertion of a long-covered biliary stent was safe and effective regardless of duodenal stent placement. • Percutaneous insertion of long-covered biliary stents in patients with malignant duodenobiliary stricture is a safe and effective procedure. • Biliary stent deployment was technically successful in all 57 patients and successful internal drainage was achieved in 55 (96.5%) of 57 patients. • The median patient survival and stent patency times were 99days and 73days, respectively, after placement of a long-covered biliary stent in patients with duodenobiliary stricture.

A81 OPTIMIZING THE INDICATIONS FOR BILIARY STENT PLACEMENT IN PATIENTS WITH CBD STONES: A QUALITY IMPROVEMENT INITIATIVE TO ENHANCE PATIENT CARE AND REDUCE HEALTHCARE RESOURCE UTILIZATION

Abstract Background A retrospective chart audit was performed to review biliary stent utilization from January 2020 to 2021 at the University of Alberta Hospital (UAH). Inappropriate stent usage was identified in 16% of patients with common bile duct (CBD) stones presenting for endoscopic retrograde cholangiopancreatography (ERCP). To improve this clinical practice, a quality improvement (QI) initiative was developed and completed. Purpose To reduce the number of inappropriately inserted biliary stents in patients with CBD stones. Method The results of the chart audit (pre-intervention) were shared with the ERCP group. The QI intervention was to align biliary stent insertion in accordance with published guidelines. A chart audit (post-intervention) was then performed on all ERCPs from July, 2021 to June, 2022. The indication for biliary stent insertion was assessed independently by two blinded reviewers. Result(s) A total of 661 patients (337 F) with mean age of 59±19 years (range 12-98 years) underwent 885 ERCPs during this post-intervention period. Of the 661 patients, 384 (58%) were referred for CBD stones. A total of 192 biliary stents (105 plastic, 85 metal) were placed during the first ERCP (192/661, 29%), as compared to the pre-intervention year (223/598, 37%, p=ns). However, only 13/192 stents (7%) were placed not in accordance with published guidelines (kappa=0.53), compared with 63/223 (28%) in the pre-intervention year (p&amp;lt;0.0001). This accounts for a 75% reduction in overall unnecessary stent placement. This reduction was mainly seen in the CBD stone subgroup, where there was an 88% reduction in inappropriate biliary stent placement compared to the pre-intervention year (8/384, 2% vs. 61/376, 16%, p&amp;lt;0.0001). Image Conclusion(s) Education to align practice in accordance with published guidelines has demonstrated a significant improvement in biliary stent insertion during ERCP in patients with CBD stones. This has resulted in significantly fewer inappropriate stent placements, a reduction in unnecessary follow-up ERCPs, and an overall saving of healthcare resources. Please acknowledge all funding agencies by checking the applicable boxes below None Disclosure of Interest None Declared

COMMON BILE DUCT STONE EXPLORATION: T-TUBE OR BILIARY

The aim of the work: to reduce hospital length of stay and morbidity after stent placement compared with T-tube drainage. Reduce costs and increase patient satisfaction with biliary stenting Materials and Methods. The study involves 52 patients with choledocholithiasis who underwent LCBDE and decompression of the biliary system by either antegrade biliary stent or T-tube insertion. A 7 French biliary stent (9 “10 cm long) have been placed in 27 patients (group I), T-tube insertion have been used for 25 patients (group II). The length of hospital stay and complications were recorded. All transcystic explorations were excluded. Results. There were no significant differences between groups with respect to age, sex, comorbidities, number and size of CBD stones. Postoperative complications have been observed in 4 patients (16 %) in the T-tube group (one patient needed reoperation for dislocation of T-tube), and in 1 patient (3.7 %) in the biliary stent group (p &lt; 0.05). The mean postoperative hospital stay was 3.2 ± 1.2 days for group I, and 6.2 ± 1.7 days for group II (p &lt; 0.05).

EGS P32V Laparoscopic transcystic Antegrade Biliary Stenting

Abstract Background Laparoscopic cholecystectomy is the gold standard treatment for symptomatic cholelithiasis including pancreatitis. Symptomatic gall stones patients have up to 20% risk of having common bile duct (CBD) stones too. Although, guidelines have been laid down for management of suspected CBD stones, in practice there is a lot of variability and lack of standardisation. The waiting list for Magnetic resonance cholangiopancreatography (MRCP) is long, resulting in delayed treatment and increased length of hospital stay. Similarly, pre-operative endoscopic retrograde cholangiopancreatography (ERCP) can also increase the length of hospital stay due to long waiting lists, limited availability and overall risk of complications as high as 30%. Hence, the role of on-table cholangiogram (OTC) while performing laparoscopic cholecystectomy has been explored. The guidelines state that OTC should be performed in fit for surgery patients, without pre-operative investigations for diagnosing CBD stones. We have been practising early cholecystectomy with on-table cholangiogram (during the index admission), with selective insertion of antegrade biliary stent in patients with choledocholithiasis. We facilitate ERCP with stent removal and clearance of CBD stones after 4 weeks post-operatively. We aim to present our technique of laparoscopic antegrade biliary stent insertion. Methods We follow the standard four-port technique for Laparoscopic cholecystectomy. Following dissection of Calot's triangle and visualisation of ‘critical view of safety’, an on-table cholangiogram is performed using a standard technique. If CBD stones are visualised, a transcystic antegrade stenting is done by Seldinger technique (without clearing the CBD of stones). The cholangiogram catheter is removed and flex-tip ureteric catheter is inserted transcystically. Through the ureteric catheter a flex-tip guidewire is inserted into CBD till its tip is visualised in the duodenum, under C-arm guidance. The ureteral catheter is then withdrawn carefully with guidewire placed satisfactorily. A double pig tail end biliary stent is rail-roaded over the guidewire, using a pushing catheter fashioned appropriately. As soon as the tip of the stent is visualised beyond the ampulla (in the X-ray), the guidewire and pushing catheter are withdrawn. The curling up of both ends of the stent is visualised and confirmed through C-arm guidance. Thereafter the procedure of cholecystectomy, as standard, is completed. Results The results of this procedure were analysed from 2014 to 2017, and subsequently published in 2018. Conclusions This technique does not involve skills required for CBD exploration. Hence, can be performed by general surgeons with expertise in minimal access surgeries, as it does not involve a steep learning curve. This technique is safe, reliable and cost-effective. It also decreases delays in biliary decompression, in-hospital stay and ensures timely treatment.

HPB P09 Forgotten ERCP Stents: Is a National Registry Required

Abstract Background Pre-operative endoscopic retrograde cholangiopancreatography (ERCP), stone removal and interval cholecystectomy is the widely practiced management for choledocholithiasis with concomitant gallstones. Biliary stenting is performed with plastic or metallic stents which require removal after 3–6 months. The sequelae from the forgotten biliary stent following laparoscopic cholecystectomy, stent occlusion, migration or cholangitis, carry significant morbidity and cost implications. Methods Pre-operative endoscopic retrograde cholangiopancreatography (ERCP), stone removal and interval cholecystectomy is the widely practiced management for choledocholithiasis with concomitant gallstones. Biliary stenting is performed with plastic or metallic stents which require removal after 3–6 months. The sequelae from the forgotten biliary stent following laparoscopic cholecystectomy, stent occlusion, migration or cholangitis, carry significant morbidity and cost implications. Results 308 laparoscopic cholecystectomies were performed in the study period. 25 (8%) underwent pre-operative biliary stenting, of these 16 underwent successful stent removal. 7 patients are still awaiting removal and 2 were discharged without stent removal and lost to follow up. One of these required emergency admission and removal of the stent at a tertiary centre due to stent complication. The average time from biliary stenting with ERCP to cholecystectomy was 99 days. The average time from cholecystectomy to removal of biliary stents was 113 days. The average length of time from insertion of biliary stent to removal was 195 days. Conclusions Where common bile duct exploration at the time of cholecystectomy is not possible we recommend ERCP units provide a stent registry system with a deadline for biliary stents in the registry system for each patient.

Prognostic nomogram for acute pancreatitis after percutaneous biliary stent insertion in patients with malignant obstruction

ObjectiveThis study aimed to develop and validate a nomogram to predict the risk of pancreatitis after percutaneous transhepatic biliary stent insertion (PTBS) in patients with malignant biliary obstruction (MBO).Materials and methodsWe enrolled 314 patients who underwent PTBS for MBO from March 2016 to July 2021 in this retrospective study. We used univariate analysis to identify potential risk factors, while a multivariate logistic regression model was employed to establish a nomogram for predicting the risk of pancreatitis. The discrimination and calibration of the nomogram were evaluated by estimating the area under the receiver operator characteristic curve (AUC) and by bootstrap resampling and visual inspection of the calibration curve. The clinical utility of the nomogram was assessed using decision curve analysis (DCA).ResultsAfter the procedure, 41 (13.1%) patients developed pancreatitis. Based on multivariate logistic regression analysis, young age (OR = 2.57, 95% CI 1.16 to 5.69), stent insertion across the papilla (OR = 6.47, 95% CI 2.66 to 15.70), and visualization of the pancreatic duct (OR = 15.40, 95% CI 6.07 to 39.03) were associated with an elevated risk of pancreatitis. Importantly, the performance of the nomogram was satisfactory, with an identical AUC (0.807, 95% CI 0.730 to 0.883) and high-level agreement between predicted and observed probabilities as suggested in calibration curves. The DCA curve subsequently confirmed the clinical utility.ConclusionA predictive nomogram for pancreatitis after PTBS in patients with MBO was successfully established in the present study.

Screening for hilar biliary invasion in ampullary cancer patients.

BACKGROUNDThe treatment for ampullary cancer is pancreatoduodenectomy or local ampullectomy. However, effective methods for the preoperative investigation of hilar biliary invasion in ampullary cancer patients have not yet been identified.AIMTo determine the necessity of and an appropriate method for investigating hilar biliary invasion of ampullary cancer.METHODSAmong 43 ampullary cancer patients, 34 underwent endoscopic treatment (n = 9) or surgery (n = 25). The use of imaging findings (thickening and enhancement of the bile duct wall on contrast-enhanced computed tomography, irregularity on endoscopic retrograde cholangiography, thickening of the entire bile duct wall on intraductal ultrasonography (IDUS), and partial thickening of the bile duct wall on IDUS) and biliary biopsy results for diagnosing hilar biliary invasion of ampullary cancer was compared.RESULTSHilar invasion was not observed in every patient. Among the patients who did not undergo biliary stent insertion, the combination of partial thickening of the bile duct wall on IDUS and biliary biopsy results showed the highest accuracy (100%) for diagnosing hilar biliary invasion. However, each imaging method and biliary biopsy yielded some false-positive results.CONCLUSIONAlthough some false-positive results were obtained with each method, the combination of partial thickening of the bile duct wall on IDUS and biliary biopsy results was useful for diagnosing hilar biliary invasion of ampullary cancer. However, hilar invasion of ampullary cancer is rare; therefore, the investigation of hilar biliary invasion of ampullary cancer might be unnecessary.

A case report of gastrointestinal perforation in patient after biliary stent insertion and the overview of gastrointestinal perforation

Objectives: This study aimed to emphasize the importance of accurate and timely diagnosis of acute abdominal pain with simple radiography by reporting a case of gastrointestinal perforation.Methods: We closely observed the diagnosis and progress of acute abdominal pain after biliary stent and reviewed the outline of gastrointestinal perforation.Results: Patient diagnosed with urethral cancer metastasis to lung and peritoneum was treated with complex Korean medicinal treatments to deal with anorexia, abdominal pain, jaundice and oliguria. During hospitalization, the patient's acute abdominal pain after biliary stent was diagnosed with gastrointestinal perforation by using plain chest and abdominal radiography.Conclusion: Using simple radiography to find out the emergency diseases such as perforation in acute abdominal pain is important clinically.

MRI-Guided Intraluminal HDR Brachytherapy for Inoperable Malignant Biliary Tract Obstruction

Aim: Malignant biliary tract obstruction (MBTO) leads to abdominal pain, jaundice, poor quality of life and portends a poor prognosis. Management of MBTO is a significant therapeutic challenge given that treatment with chemotherapy or radiotherapy has limited utility and percutaneous biliary drainage or stent insertion provides only transient symptomatic relief. Intraluminal HDR brachytherapy via catheters inserted percutaneously at the time of stent insertion can be effective in the management of inoperable MBTO. Here, we describe the workflow developed within our department for simulation and treatment using an intraluminal brachytherapy technique. Process: Delivery of bile duct brachytherapy requires the participation of multiple disciplines including interventional radiology (IR), medical physics, radiation oncology (RO) and radiation therapy with careful coordination of numerous tasks. A drain/stent and 1-2 treatment catheters are inserted into the patient's bile ducts by IR before the CT and MR simulation (sim). During the CT sim, multiple surview and low dose helical scans are acquired to verify the treatment catheter position and adjustments are made by the RO as needed. Once the position is finalized, a planning CT scan is done with IV contrast and the patient in voluntary breath hold. Then, the CT and MR sim images are fused. The CT is used to digitize the brachytherapy source path, while the MR is used for target and organs at risk delineation. Treatment is delivered 1-2 days after sim, with 15-25 Gy in 3-5 fractions using an Ir-192 HDR source. Radiographs are taken to confirm catheter position prior to each treatment. Benefits/Challenges: Brachytherapy can be used to treat the tumor at the same time as placement of a stent/drain, thus providing both symptom management and disease control. Although the patient is admitted for the IR procedure, the actual brachytherapy treatment is done on an outpatient basis with no anesthesia, thus treatment does not require significant time or resources in the brachytherapy suite. Patients often present with biliary obstruction emergently and stent/drain placement is booked urgently in IR with little notice to the radiotherapy department. The tight time line makes it difficult to facilitate communication between the multidisciplinary team, prepare staff, assemble supplies, and coordinate subsequent appointments. The CT sim process continues to evolve as new issues are identified with each patient. Variations in catheter/stent placement is a potential challenge and 2/8 patients have required reinsertion of angio-sheath by IR after problems were discovered during the CT sim. MR sim is not always possible depending on nature of inserted material (i.e. metallic stent or drainage sheath). Treatment catheters must be secured in place and covered with a dressing between appointments to prevent damage, change in position or obstruction. Patient education and cooperation is crucial to ensure proper care. Impact/Outcomes: In April 2021, our institution became the first in Canada to offer MRI-guided brachytherapy treatment for patients with inoperable MBTO. As of Jan 2022, 8 patients have been treated using this protocol. With each subsequent case, the time required for treatment delivery has decreased from 1 hour to 30 minutes per fraction and sim processes optimized. This treatment option has potential to improve the quality of life in patients with minimal therapeutic options.

Biliopleural fistula following percutaneous transhepatic cholangiodrainage and irradiation biliary stent insertion successfully treated with coil embolization: a case description.

Biliopleural fistula following percutaneous transhepatic cholangiodrainage and irradiation biliary stent insertion successfully treated with coil embolization: a case description.

Real-life patency of plastic biliary stents in the pandemic era: is stent removal after 6 months safe and effective?

Background The SARS-CoV-2 pandemic conditioned the optimal timing of some endoscopic procedures. ESGE guidelines recommend replacement or removal of the plastic biliary stents within 3–6 months to reduce the risk of complications. Our aim was to analyse the outcomes of patients who had delayed plastic biliary stent removal following endoscopic retrograde cholangiopancreatography (ERCP) in the pandemic era. Methods Retrospective study including consecutive ERCPs with plastic biliary stent placement between January 2019 and December 2021. Delayed removal was defined as presence of biliary stent >6 months after ERCP. The evaluated outcomes were stent migration, stent dysfunction, obstructive jaundice, cholangitis, acute pancreatitis, hospitalization, and biliary pathology-related mortality. Results One-hundred and twenty ERCPs were included, 56.7% male patients, with a mean age of 69.4 ± 15.7 years. Indications for plastic biliary stent insertion were choledocholithiasis (72.5%), benign biliary stricture (20.0%), and post-cholecystectomy fistula (7.5%). Delayed stent removal occurred in 32.5% of the cases. The median time to stent removal was 3.5 ± 1.3 months for early removal and 8.6 ± 3.1 months for delayed removal. Patients who had delayed stent removal did not have a significantly higher frequency of stent migration (20.5 vs 11.1%, p = 0.17), stent dysfunction (17.9 vs 13.6%, p = 0.53), hospitalization (17.9 vs 14.8%, p = 0.66), obstructive jaundice (2.6 vs 0.0%, p = 0.33), cholangitis (10.3 vs 13.6%, p = 0.77), acute pancreatitis (0.0 vs 1.2%, p = 1.0), or biliary pathology-related mortality (2.6 vs 1.2%, p = 0.55). Conclusions Delayed plastic biliary stent removal does not seem to have a negative impact on patients’ outcomes. In the current pandemic situation, while scheduled endoscopic procedures may have to be postponed, elective removal of plastic biliary stents can be safely deferred.

Duodenal perforation secondary to stent migration after ERCP for hepatobiliary tuberculosis: Case report of a lethal complication in a young patient.

IntroductionInterventional internal drainage of the biliary tract has become an established procedure for the temporary and definitive treatment of biliary obstruction due to malignant or benign disease. The complication rate is reported to be so low that when feasible, this technique is preferred over a surgical drainage procedure.Presentation of a caseA 26-year old woman was referred to the hepatopancreaticobiliary surgery service due to severe abdominal pain for 3 days after undergoing endoscopic retrograde cholangiopancreatography (ERCP). She underwent biliary dilatation and stent insertion for obstructive jaundice secondary to biliary stricture from hepatobiliary tuberculosis. The patient underwent exploratory laparotomy, peritoneal lavage, duodenorrhaphy and tube jejunostomy for bilious peritonitis and duodenal perforation from biliary stent migration. The patient died one day post-operation due to septic shock from secondary bacterial peritonitis.DiscussionERCP and other interventional endoscopic biliary interventions are increasingly being used for biliary obstruction. Despite the various complications which arise from these diagnostic and therapeutic modalities, complications are relatively uncommon. Duodenal perforation from biliary stent migration is a rare complication after undergoing ERCP and stenting. However, in patients presenting with severe pain and physical signs of acute abdomen after the procedure, it should always be a consideration.ConclusionsDespite the relative safety of interventional techniques for biliary obstruction, complications like pancreatitis, hemorrhage and perforation may occur. Early recognition and high index of suspicion allows for early intervention with good outcomes. Duodenal perforation from stent migration can occur and when intervention is delayed may lead to morbidity and mortality.

Percutaneous cholecystostomy for acute cholecystitis after stent insertion in patients with malignant biliary obstruction: clinical outcomes of 107 patients.

The outcome of percutaneous cholecystostomy (PC) in malignant patients with acute cholecystitis (AC) after biliary stent insertion has not been investigated in a large group. To evaluate the clinical outcomes of PC for AC after stent insertion in patients with malignant biliary obstruction. From April 2007 to February 2019, 107 patients (57 men, 52 women; mean age = 67.5 years; age range = 27-93 years) who had undergone PC for AC after biliary stent insertion were retrospectively evaluated. Of the 107 patients, 86 underwent biliary stent insertion by the endoscopic approach and the remaining 21 patients by the percutaneous approach. All patients were classified into three groups: those with stent-induced AC; those with cancer-induced AC; and those with AC without mechanical cause (biliary stent, GB stone, or cancer invasion). The mean survival time, recurrence rate, symptom improvement, and cystic duct patency in each patient group were analyzed. Stent-induced AC (n = 40, 37.4%) developed with a mean onset time of six days (range = 0-14 days), AC without mechanical cause (n = 27, 25.2%), 87 days (range = 15-273 days), and cancer-induced AC (n = 40, 37.4%), 137 days (range = 15-447 days) after stent insertion. Symptom resolution and significant improvement in laboratory test values were achieved in 95 patients (88.8%) within four days after PC. PC is a technically safe and effective method for the treatment of AC after biliary stent insertion in patients with malignant biliary obstruction.

S2555 Right Hepatic Artery Pseudoaneurysm: A Rare Complication of Biliary Stent Placement

Introduction: Formation of pseudoaneurysm is a rare but serious adverse event of biliary stenting. We present a case of a patient who presented with massive upper gastrointestinal bleeding two months after biliary stent insertion. Angiography revealed a right hepatic artery pseudoaneurysm which was successfully treated with transcatheter arterial embolization. Because bleeding may be fatal, timely diagnosis of the condition is important. Case Description/Methods: A 65-year-old-man with a past medical history of recurrent gallstone pancreatitis underwent Endoscopic Retrograde Cholangio-Pancreatography (ERCP) with sphincterotomy and fully covered metal stent placement was admitted to our hospital for severe hematemesis. Labs revealed a drop in hemoglobin from 7.6 to 5.8. After endotracheal intubation, activation of the massive transfusion protocol (MTP) Minnesota tube placement, emergent esophagogastroduodenoscopy (EGD) was performed at the bedside, which showed a large amount of clotted blood but no active bleed. The next day, again he developed severe upper gastrointestinal bleeding leading to hypovolemic shock. MTP was activated again, and a Minnesota tube reinserted. After intensive resuscitation, a computed tomography angiography (CTA) was performed which showed a 6 cm large bilobed pseudoaneurysm in the porta hepatis appears to be arising from the hepatic artery. Successful embolization of the common hepatic artery was performed without complications. No recurrent bleeding occurred over the following days. Discussion: This case demonstrates a rare complication of biliary stents which was successfully treated with transcatheter arterial embolization. It is important to consider that a pseudoaneurysm is a potential adverse event caused by a biliary stent because timely diagnosis and treatment are required to prevent fatal hemorrhage and death.Figure 1.: A. Large bilobed pseudoaneurysm in the porta hepatis appears to be arising from the hepatic artery and abuts the distal gastric antrum/proximal duodenum. B. Injection from celiac artery demonstrating a bilobed pseudoaneurysm originating from the common hepatic artery/proximal right hepatic artery at the level of the intersection with the biliary stent. C. Post IR embolization CTA showing common hepatic artery without opacification and previously seen pseudoaneurysm.